Cardiovascular Business September 11, 2024
Johnson & Johnson has officially completed a major transition, announcing that Biosense Webster, Abiomed, Cerenovus and some of its other healthcare technology companies will now go by the name Johnson & Johnson MedTech.
Johnson & Johnson first announced its agreement to acquire Biosense Webster for $400 million in shares back in 1997, and Cerenovus was launched in 2017 after the company combined its acquisitions of Pulsar Vascular and Neuravi. The decision to buy Abiomed, meanwhile, came in November 2022.
Now, these companies—in addition to Ethicon and DePuy Synthes—are all under the Johnson & Johnson umbrella.
“By bringing our medtech businesses together under the Johnson & Johnson name, the scale of our impact in healthcare will be even...
Today's Sponsors
Today's Sponsor